Eton Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. (ticker: ETON) is a U.S.-listed specialty pharmaceutical company traded on the NASDAQ in the United States. Headquartered in Deer Park, Illinois, Eton was incorporated in 2017 as a separate entity emerging from the Imprimis/Harrow Health ecosystem, and it originally focused on hospital injectables and rare-disease therapies. Its business model is built around acquiring, developing, and commercializing niche prescription products, often using the FDA 505(b)(2) pathway to bring differentiated therapies to market faster than a traditional de novo development program. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1710340/000161577418012575/s114004_424b4.htm?utm_source=openai)) Today, Eton positions itself as a rare-disease and ultra-rare-disease company with a portfolio that combines marketed products, licensing revenue, and late-stage development assets. The company’s marketed products include ALKINDI SPRINKLE, INCRELEX, KHINDIVI, HEMANGEOL, GALZIN, CARGLUMIC ACID, BETAINE, NITISINONE CAPSULES, PKU GOLIKE, and TYR GOLIKE. This breadth gives Eton a commercial base while also supporting a pipeline-driven growth story. The company’s revenue mix is therefore more diversified than that of a pure R&D biotech, but still concentrated in a relatively small set of specialty products. ([etonpharma.com](https://www.etonpharma.com/products/)) From a competitive standpoint, Eton is a small-cap specialist rather than a broad-based pharma platform. Its advantage lies in focus, regulatory agility, and the ability to identify under-served markets where a new formulation, a relaunch, or a rights acquisition can create value. At the same time, the company faces the typical risks of a niche pharmaceutical business: dependence on a limited number of products, regulatory timing risk, commercial execution risk, and pricing/reimbursement pressure. Eton’s current strategy reflects a blend of product acquisition, in-house development, and selective out-licensing, aimed at building a durable rare-disease franchise. ([etonpharma.com](https://www.etonpharma.com/products/)) Recent developments suggest meaningful momentum. In 2025, Eton reported continued sequential growth in product sales, moved GALZIN into its own commercial distribution infrastructure, submitted an NDA for ET-600, and out-licensed ex-U.S. rights to INCRELEX to Esteve Pharmaceuticals. The company also highlighted several expected product launches and additional late-stage programs. Its latest annual report confirms the company remains based in Deer Park, Illinois, and notes that Medicare exposure is limited because only a small portion of Eton’s products are prescribed to Medicare patients. For French, Belgian, and Swiss investors, ETON is therefore best viewed as a NASDAQ-listed United States specialty pharma company with a rare-disease focus, a modest commercial footprint, and a pipeline geared toward high-value niche indications. ([ir.etonpharma.com](https://ir.etonpharma.com/static-files/8bea9cbb-49a6-4242-8f74-af05c5036636))